News

Under the terms of the agreement, Verastem Oncology shall receive an upfront payment of $5 million USD. Verastem Oncology is also eligible to receive up to an additional

Epizyme has proposed an indication of metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery. The FDA granted Priority Review for the NDA and has set

Under the deal, Zambon has made an upfront payment of €140m (£125m) to acquire Breath Therapeutics and its subsidiaries and the acquisition value could increase to €500m (£446m)

Full Week 48 findings were presented today at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City. Kimberly Smith, MD, Head of Global

The part one of the phase 3 CheckMate -227 trial assessing Opdivo plus low-dose Yervoy (ipilimumab) achieved the co-primary endpoint of overall survival (OS). According to the company,

Upon completion of the merger, Gemphire will change its name to NeuroBo Pharmaceuticals, Inc., and plans to change its ticker symbol on the Nasdaq Capital Market to “NRBO.”

Ab Initio was a privately held antigen-discovery company based in South San Francisco, California. Antigen design and preparation are the first steps necessary for the discovery of therapeutic

The breakthrough therapy designation for the Keytruda, Lenvima combo is for the first-line treatment of patients with advanced unresectable HCC that is not responsive to locoregional treatment. Keytruda

Ruxience, a monoclonal antibody (mAb), has been approved to treat non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Ruxience works